Issued by Novartis
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.
The report is based on the results of the CR materiality analysis review conducted in 2015, which reconfirmed that access, ethics, and research and development are our most important issues. In addition, it offers insights into how Novartis manages CR, including the company’s access framework, showing the variety of approaches and models used to expand access to healthcare globally.
Novartis 2015 CR highlights:
Launched Novartis Access, a portfolio of 15 medicines to treat the main noncommunicable diseases in lower-income countries at a cost of USD 1 per treatment per month
Provided medicine to 66 million patients through access programs
Reached 7.6 million people through social business initiatives in India, Kenya, Vietnam and Indonesia
Launched a new Group-wide program to ensure our ethical standards are firmly embedded in our business practices
Trained more than 110 000 Novartis associates on the company’s Code of Conduct
Set a new 2030 company vision on environmental sustainability with a 30% reduction target in global greenhouse gas emissions by 2020 vs. 2010
Recognized in major CR-related indices, such as Dow Jones Sustainability Index and FTSE4Good, as well as, most recently, in the Global 100 Most Sustainable Corporations in the World Index by Corporate Knights
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
More from Novartis